Singapore markets closed

Lonza Group AG (LZAGY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
53.17+0.53 (+1.01%)
At close: 12:46PM EST
Full screen
Trade prices are not sourced from all markets
Previous close52.64
Open52.90
Bid0.00 x 0
Ask0.00 x 0
Day's range52.78 - 53.34
52-week range43.85 - 84.16
Volume357,725
Avg. volume156,782
Market cap39.56B
Beta (5Y monthly)0.71
PE ratio (TTM)41.54
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield0.30 (0.57%)
Ex-dividend date09 May 2022
1y target estN/A
  • Reuters

    Lonza's first-half core EBITDA gains 16.5%

    (Reuters) -Swiss drug contract manufacturer Lonza said first-half core earnings gained 16.5% on strong demand from biopharmaceutical companies. First-half core earnings - adjusted for interest, tax, depreciation and amortisation - (EBITDA) rose to 987 million Swiss francs ($1.02 billion), it said in a statement on Friday, beating an analyst consensus of about 940 million francs. For this year, Lonza said it was still targeting "low to mid-teens" sales growth, when excluding currency swings, as well as an improvement in the core EBITDA margin that is consistent with a 2024 goal of 33%-35%, up from 30.8% in 2021.

  • Reuters

    Lonza's full-year core EBITDA up 20.7% on vaccine demand

    (Reuters) -Swiss drug contract manufacturer Lonza said core earnings gained 20.7% in 2021, shored up by demand for the substances it supplies for new mRNA COVID-19 vaccines. Full-year core earnings before interest, tax, depreciation and amortisation (EBITDA) rose to 1.67 billion Swiss francs ($1.82 billion), up from 1.38 billion a year earlier, it said in a statement on Wednesday. For this year, Lonza predicted "low to mid-teens" sales growth, when excluding currency swings, as well as core EBITDA margin improvement from 30.8% in 2021.